Tri Locum Partners’s Ascendis Pharma A/S ASND Stock Holding History

Tri Locum Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69M	Buy	258,740 +3,408	+1%	+$796K	8.49%	4
2026 Q1	$58.4M	Sell	255,332 -9,683	-4%	-$2.17M	8.2%	4
2025 Q4	$56.5M	Buy	265,015 +90,186	+52%	+$18.6M	7.34%	5
2025 Q3	$34.8M	Buy	174,829 +27,187	+18%	+$5.07M	7.99%	5
2025 Q2	$25.5M	Buy	147,642 +115,317	+357%	+$18.8M	7.73%	5
2025 Q1	$5.04M	Buy	+32,325	New	+$4.62M	2.59%	15
2024 Q3	–	Sell	-227,762	Closed	-$31.1M	–	23
2024 Q2	$31.1M	Buy	227,762 +115,092	+102%	+$15.7M	7.85%	3
2024 Q1	$17M	Buy	112,670 +13,120	+13%	+$1.87M	5.91%	5
2023 Q4	$12.5M	Buy	+99,550	New	+$9.93M	5.73%	6
2023 Q1	–	Sell	-99,215	Closed	-$12.1M	–	53
2022 Q4	$12.1M	Buy	+99,215	New	+$11.5M	4.9%	7

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Tri Locum Partners's ASND Position: Q2 2026 in Review

Tri Locum Partners increased its Ascendis Pharma A/S (ASND) stake by 1.3% in Q2 2026, buying an estimated $796K and bringing the position to 258,740 shares worth $69M. The position accounts for 8.49% of the portfolio, ranked #4.

Tri Locum Partners first reported a position in ASND in Q4 2022 and has held it in 10 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Tri Locum Partners held 258,740 shares of Ascendis Pharma A/S worth $69M as of Q2 2026.
Tri Locum Partners bought 3,408 Ascendis Pharma A/S shares in Q2 2026, an estimated $796K.
Ascendis Pharma A/S made up 8.49% of Tri Locum Partners's portfolio in Q2 2026, its #4 holding.
Tri Locum Partners first reported a position in Ascendis Pharma A/S in Q4 2022 and has held it in 10 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.